Operational Highlights
The company's weekly production has outpaced the fourth quarter, and it is anticipating travel to be flat to up slightly on a sequential basis. The growing book of business and robust pipeline of sales activity across multiple business lines are expected to drive revenue growth. The company's proprietary technology portfolio, anchored by Intellify, has delivered predictive visibility, optimized clinician deployment, and improved labor cost management for health systems.
Guidance and Outlook
For the first quarter of 2026, the company is guiding to revenue of between $235 million and $240 million, with an adjusted EBITDA range of between $4 million and $8 million. The company expects to return to revenue and earnings growth by the end of 2026, driven by organic revenue growth across all lines of business, cost containment efforts, and efficiencies through technology. Analysts estimate next year's revenue growth at 4.8%.
Valuation
With a P/E Ratio of -3.35, P/B Ratio of 0.98, and P/S Ratio of 0.31, the company's valuation metrics indicate a potentially undervalued stock. The EV/EBITDA ratio of 16.15 suggests that the company's enterprise value is relatively high compared to its EBITDA. The company's ROE and ROIC are negative, indicating that the company is not generating returns on its equity and invested capital. As per William Burns, the company is "looking to exit the year with fourth quarter revenue above $250 million and an adjusted EBITDA margin of between 4% and 5%."
Growth Initiatives
The company plans to expand Intellify into the home-based and education staffing markets, extending its reach into adjacent sectors that demand scalable workforce solutions. The company is also investing in AI technology, leveraging Agentic AI in delivery and recruitment, and using AI technology in the locums business for credentialing. This is expected to help accelerate delivery speed and take costs out of the company, leading to growing EBITDA margins.